DZHK studies and associated studies

In the MR SPOC trial, modern smartwatches continuously measure ECG, pulse, and oxygen saturation in the blood of COVID-19 patients and transfer these data into the hospital to get treatment advice.

The Germany-wide COVIDPREVENT trial is investigating whether the administration of the blood thinner Rivaroxaban can reduce thrombotic events such as heart attack, pulmonary embolism or stroke in CoVID-19 patients.

The study investigates the effects on the course of COVID-19 disease when ACE inhibitors are paused or replaced by antihypertensives with a different mechanism of action in COVID-19 patients.

TORCH-Plus is a large-scale prospective data & biospecimen repository of patients with non-ischemic cardiomyopathies.

BioVAT-HF-DZHK20 trial is investigating under which conditions engineered human myocardium is safe to use in the treatment of patients with end-stage heart failure.

The associated DZHK study PASSION investigates whether the drug Tadalafil can reduce cardiac-related hospital admissions and mortality of patients with pulmonary hypertension due to heart failure.

The aim of the study PRAISE-DZHK19 I DZNEB001 is to establish a clinical algorithm that enables the prediction of acute coronary syndrome or heart attack in stroke patients.

The METRIS-HF-DZHK18 trial aims to find out whether improved energy metabolism can increase heart efficiency in patients with cardiac insufficiency.

The SCREEN-AF study aims to improve the early detection of atrial fibrillation using a new “rhythm patch” with an integrated ECG recording unit which is applied to the patient’s chest.

The aim of the study is to clarify whether it is beneficial to operate the tricuspid valve in the right heart at the same time if the mitral valve is defective, even if the right heart valve is not yet very leaky.

The DECIPHER HFpEF-DZHK12 study investigates whether diastolic heart failure can be better diagnosed and its causes clarified with the help of cardiovascular magnetic resonance imaging (CMR).

This study is examining whether a tailored physical exercise can improve the fitness and quality of life of patients with an artificial heart.

The DEDICATE-DZHK6 study is investigating whether surgical or transcatheter aortic valve implantation is the superior long-term treatment option for patients with severe aortic valve stenosis.

This trial is examining whether an ultrasound evaluation of the inferior vena cava in acute decompensated heart failure (ADHF) with congestion can be implemented in hospitals’ everyday routine in a large number of patients.

Researchers will test in this trial whether the newly developed real-time CMR technology is suitable for the early and safe diagnosis of HFpEF.

The DZHK study CLOSURE-AF compares the benefit of the left atrial appendage closure with the best possible drug therapy for high-risk patients with atrial fibrillation.

The SPIRIT-HF-DZHK8 study investigates whether the drug spironolactone can reduce the number of people with preserved ejection fraction who end up in hospital and the number of people who die from heart failure.

DZHK researchers from Munich test whether the use of implantable cardiac monitors with home monitoring function is more effective than conventional follow-up for detecting serious arrhythmic events in a newly identified high-risk group of patients.

DZHK researchers compare two therapies in patients with atrial fibrillation, who have also had a heart attack in order to find out which therapy leads to less bleedings.

The FAIR-HF2 study will be assessing whether treatment with intravenously administered ferric carboxymaltose improves the chances of survival and helps to reduce the number of hospitalisations of heart failure patients diagnosed with iron deficiency.

TOMAHAWK compares the effects of immediate coronary angiography to delayed intervention in survivors of cardiac arrest who occurred outside a hospital and without ST elevation.

This study is expected to deliver guideline-relevant findings for the future treatment of patients with terminal heart failure.

This cohort study explores ways of predicting when decreased cardiac performance without symptoms will develop into a clinically manifest disease.

As a translational registry for cardiomyopathies, TORCH-DZHK1 collects data and biosamples from 2,300 patients with heart muscle diseases.

The study objective is to evaluate the efficacy and safety of treatment of the drug Revacept versus placebo in patients with stable coronary artery disease undergoing PCI.

The cohort study SFB/TR 19 plus investigates new diagnostic and treatment approaches for inflammatory cardiomyopathies.

This study compares two agents used to inhibit blood clotting - ticagrelor and prasugrel. The hypothesis that ticagrelor is superior to prasugrel for the treatment of patients with acute coronary syndrome will be examined in relation to clinical outcomes.

Prospective randomized multicenter study comparing immediate multivessel revascularization by PCI versus culprit lesion PCI with staged non-culprit lesion revascularization in patients with acute myocardial infarction complicated by cardiogenic shock.

Prospective randomized multicenter study to evaluate the impact of weight reduction on AF recurrence after AF ablation in obese patients.

The study was designed to evaluate both safety and efficacy of the OPTIMIZER system in patients with moderate to severe heart failure.

NOAH-AFNET 6 evaluates the potential benefit of oral anticoagulation treatment in patients with atrial high rate episodes.

The person-based register records data from patients of all age groups and with all kinds of congenital heart defects across Germany.